CL2022001742A1 - 25-hidroxi-colest-5-en-3-sulfato de sodio cristalino y cristalino líquido y métodos para preparar los mismos - Google Patents
25-hidroxi-colest-5-en-3-sulfato de sodio cristalino y cristalino líquido y métodos para preparar los mismosInfo
- Publication number
- CL2022001742A1 CL2022001742A1 CL2022001742A CL2022001742A CL2022001742A1 CL 2022001742 A1 CL2022001742 A1 CL 2022001742A1 CL 2022001742 A CL2022001742 A CL 2022001742A CL 2022001742 A CL2022001742 A CL 2022001742A CL 2022001742 A1 CL2022001742 A1 CL 2022001742A1
- Authority
- CL
- Chile
- Prior art keywords
- crystalline
- forms
- 25hc3s
- cholest
- hydroxy
- Prior art date
Links
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title abstract 2
- 239000007788 liquid Substances 0.000 title abstract 2
- 229910052708 sodium Inorganic materials 0.000 title abstract 2
- 239000011734 sodium Substances 0.000 title abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 4
- PIUZYOCNZPYXOA-ZHHJOTBYSA-N [(3s,8s,9s,10r,13r,14s,17r)-17-[(2r)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)(C)O)C)[C@@]1(C)CC2 PIUZYOCNZPYXOA-ZHHJOTBYSA-N 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000033626 Renal failure acute Diseases 0.000 abstract 1
- 201000011040 acute kidney failure Diseases 0.000 abstract 1
- 208000002353 alcoholic hepatitis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
En el presente documento se describen formas cristalinas y líquidas cristalinas de 25HC3S de sodio. La descripción incluye las Formas I, II, III, V, IX, XI y XIII de 25HC3S de sodio y combinaciones de los mismas. Las formas farmacéuticas de las formas, o combinaciones de las mismas, y métodos para tratar o prevenir enfermedades tales como hipercolesterolemia, hipertrigliceridemia y afecciones relacionadas con la acumulación de grasa y la inflamación (por ejemplo, enfermedad del hígado graso no alcohólico (EHGNA), esteatohepatitis no alcohólica (EHNA), hepatitis alcohólica, lesión renal aguda (IRA), psoriasis y aterosclerosis) se describen adicionalmente en el presente documento. También se proporcionan métodos para preparar 25HC3S.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962954279P | 2019-12-27 | 2019-12-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022001742A1 true CL2022001742A1 (es) | 2023-03-24 |
Family
ID=76575692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001742A CL2022001742A1 (es) | 2019-12-27 | 2022-06-24 | 25-hidroxi-colest-5-en-3-sulfato de sodio cristalino y cristalino líquido y métodos para preparar los mismos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230056273A1 (es) |
| EP (1) | EP4081028A4 (es) |
| JP (1) | JP2023508985A (es) |
| KR (1) | KR20220119459A (es) |
| CN (1) | CN115103591A (es) |
| AU (1) | AU2020415462A1 (es) |
| BR (1) | BR112022011358A2 (es) |
| CA (1) | CA3165765A1 (es) |
| CL (1) | CL2022001742A1 (es) |
| IL (1) | IL294286A (es) |
| MX (1) | MX2022008065A (es) |
| TW (1) | TW202135829A (es) |
| WO (1) | WO2021133976A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021133976A1 (en) * | 2019-12-27 | 2021-07-01 | Durect Corporation | Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same |
| KR20240040457A (ko) | 2022-09-21 | 2024-03-28 | 현대모비스 주식회사 | 에어백 장치 및 그 전개 제어방법 |
| WO2024138203A1 (en) * | 2022-12-23 | 2024-06-27 | Durect Corporation | 25-hydroxy-cholest-5-en-3-sulfate choline, formulations thereof and methods for preparing, and medical uses of same |
| WO2024136884A1 (en) * | 2022-12-23 | 2024-06-27 | Durect Corporation | Salts including crystalline salts of 25-hydroxy-cholest-5-en-3-sulfate and methods for preparing same |
| EP4417616A1 (en) | 2023-02-14 | 2024-08-21 | Ospedale San Raffaele S.r.l. | Lxr antagonists |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5218700B2 (es) * | 1973-02-16 | 1977-05-24 | ||
| US4046760A (en) * | 1976-07-01 | 1977-09-06 | Merck & Co., Inc. | Process for preparing 1-α-hydroxy cholesterol derivatives |
| GB1592170A (en) * | 1977-01-07 | 1981-07-01 | Hoffmann La Roche | 1a-hydroxycholecalciferol-25-hydroxy esters and their use in radioimmunoassay |
| OA06115A (fr) * | 1978-03-11 | 1981-06-30 | Etat Du | Procédé de réparation du dihydroxy-24,25 cholestérol . |
| WO2006047022A1 (en) * | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| WO2008156654A2 (en) * | 2007-06-15 | 2008-12-24 | Massachusetts Institute Of Technology | Cytoskeleton modulators for treating metabolic disorders |
| US9034859B2 (en) * | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
| KR102530119B1 (ko) * | 2013-12-24 | 2023-05-08 | 버지니아 커먼웰스 유니버시티 | 산소첨가된 콜레스테롤 술페이트 (ocs) 의 용도 |
| WO2021133976A1 (en) * | 2019-12-27 | 2021-07-01 | Durect Corporation | Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same |
-
2020
- 2020-12-23 WO PCT/US2020/066947 patent/WO2021133976A1/en active Application Filing
- 2020-12-23 CA CA3165765A patent/CA3165765A1/en active Pending
- 2020-12-23 BR BR112022011358A patent/BR112022011358A2/pt unknown
- 2020-12-23 IL IL294286A patent/IL294286A/en unknown
- 2020-12-23 CN CN202080095990.5A patent/CN115103591A/zh active Pending
- 2020-12-23 EP EP20907564.7A patent/EP4081028A4/en active Pending
- 2020-12-23 MX MX2022008065A patent/MX2022008065A/es unknown
- 2020-12-23 US US17/783,248 patent/US20230056273A1/en active Pending
- 2020-12-23 AU AU2020415462A patent/AU2020415462A1/en active Pending
- 2020-12-23 KR KR1020227025318A patent/KR20220119459A/ko unknown
- 2020-12-23 JP JP2022539174A patent/JP2023508985A/ja active Pending
- 2020-12-24 TW TW109145999A patent/TW202135829A/zh unknown
-
2022
- 2022-06-24 CL CL2022001742A patent/CL2022001742A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202135829A (zh) | 2021-10-01 |
| WO2021133976A1 (en) | 2021-07-01 |
| CN115103591A (zh) | 2022-09-23 |
| IL294286A (en) | 2022-08-01 |
| BR112022011358A2 (pt) | 2022-08-23 |
| EP4081028A4 (en) | 2024-03-06 |
| JP2023508985A (ja) | 2023-03-06 |
| MX2022008065A (es) | 2022-07-27 |
| KR20220119459A (ko) | 2022-08-29 |
| AU2020415462A1 (en) | 2022-06-23 |
| US20230056273A1 (en) | 2023-02-23 |
| CA3165765A1 (en) | 2021-07-01 |
| EP4081028A1 (en) | 2022-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022001742A1 (es) | 25-hidroxi-colest-5-en-3-sulfato de sodio cristalino y cristalino líquido y métodos para preparar los mismos | |
| EA201991399A1 (ru) | Аминотриазолопиридиновые соединения и их применение в лечении рака | |
| EA202092003A1 (ru) | Соединения для лечения болезни гентингтона | |
| CL2017002727A1 (es) | Composiciones de ácido obeticólico y métodos de uso | |
| EA201800367A1 (ru) | Способы лечения болезни хантингтона | |
| CL2016002517A1 (es) | Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica. | |
| PE20210920A1 (es) | Formas solidas de un inhibidor de fgfr y procesos para prepararlas | |
| EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
| EA201790124A1 (ru) | Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения | |
| BR112016026809A2 (pt) | compostos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol substituído como agentes de alvejamento de asgpr | |
| CU20190080A7 (es) | Derivados de isoindolina útiles para tratar la esteatohepatitis no alcohólica y otras enfermedades de curación disfuncional del tejido y fibrosis | |
| BR112014006220A2 (pt) | composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica | |
| MX2018004043A (es) | Prevencion, tratamiento y reversion de enfermedad usando cantidades terapeuticamente efectivas de acidos grasos activados. | |
| EA201692292A1 (ru) | Соединения и композиции для стимулирования хондрогенеза | |
| NI201600176A (es) | Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer. | |
| EA201792034A1 (ru) | Замещенные трициклические гетероциклические соединения | |
| EA201692402A1 (ru) | Лекарственные формы для местного применения и их использование | |
| EA201990678A1 (ru) | Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2 | |
| GT201700126A (es) | Ácidos piridil-cicloalquil-carboxílicos sustituidos composiciones que los contienen y usos de los mismos | |
| EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида | |
| EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
| EA202090164A1 (ru) | Изотретиноиновые перорально-слизистые композиции и способы их применения | |
| EA202092185A1 (ru) | Ингибиторы секреции белка на основе триазациклододекансульфонамида ("tcd") | |
| CO2020012484A2 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") | |
| EA202191103A1 (ru) | Терапевтические соединения |